Javier Gavira Díaz, Specialist in oncology at Catalan Institute of Oncology (ICO), shared on LinkedIn about a recent article published in EJC:
“New study published in the European Journal of Cancer!
This EU multicenter study evaluated the activity of lenvatinib in 133 previously treated patients with metastatic RCC kidney cancer.
Key findings:
- Lenvatinib showed significant activity across different regimens, with nearly 30% objective responses.
- More than 25% of patients remained on treatment for at least 12 months, while 35% required dose adjustments.
- It also demonstrated efficacy after immunotherapy and TKI in refractory RCC.
Huge thanks to all the authors, authorities, and patients from three countries who made this study possible 🇫🇷 🇪🇸 🇬🇧.
A special thanks to Prof. Laurence Albiges and Dr. Ronan Flippot from Gustave Roussy for their mentorship and support, as well as the DUERTECC program, which allowed me to undertake a research fellowship at this incredible institution. Thank you very much for this unique opportunity.”
Authors: Javier Gavira et al.
